Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types

Mol Cancer Ther. 2020 Sep;19(9):1889-1897. doi: 10.1158/1535-7163.MCT-20-0094. Epub 2020 Jun 9.

Abstract

Next-generation sequencing of solid tumors has revealed variable signatures of immunogenicity across tumors, but underlying molecular characteristics driving such variation are not fully understood. Although expression of endogenous retrovirus (ERV)-containing transcripts can provide a source of tumor-specific neoantigen in some cancer models, associations between ERV levels and immunogenicity across different types of metastatic cancer are not well established. We performed bioinformatics analysis of genomic, transcriptomic, and clinical data across an integrated cohort of 199 patients with metastatic breast, colorectal, and pancreatic ductal adenocarcinoma tumors. Within each cancer type, we identified a subgroup of viral mimicry tumors in which increased ERV levels were coupled with transcriptional signatures of autonomous antiviral response and immunogenicity. In addition, viral mimicry colorectal and pancreatic tumors showed increased expression of DNA demethylation gene TET2 Taken together, these data demonstrate the existence of an ERV-associated viral mimicry phenotype across three distinct metastatic cancer types, while indicating links between ERV abundance, epigenetic dysregulation, and immunogenicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Computational Biology / methods*
  • DNA-Binding Proteins / genetics*
  • Dioxygenases
  • Endogenous Retroviruses / genetics*
  • Epigenesis, Genetic
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Genomics
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Neoplasm Metastasis / genetics*
  • Neoplasm Metastasis / immunology
  • Proto-Oncogene Proteins / genetics*
  • RNA, Viral / genetics
  • Sequence Analysis, RNA
  • Survival Analysis
  • Up-Regulation

Substances

  • DNA-Binding Proteins
  • Proto-Oncogene Proteins
  • RNA, Viral
  • Dioxygenases
  • TET2 protein, human

Grants and funding